An Open-Label Exploratory Phase 2/3 Study of
Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8), NCT03414983
PURPOSE OF THIS CLINICAL RESEARCH TRIAL:
This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).
MORE DETAILS ON THIS TRIAL:
17186 / NCT03414983 / Open 3-16-18